Skip to content

MBX Biosciences, Inc. MBX Enterprise value

Enterprise value at other companies

Eli Lilly logo
Eli LillyLLY
$859.77B+10.6%
Amgen logo
AmgenAMGN
$246.43B+9.9%
Viking Therapeutics logo
Viking TherapeuticsVKTX
$3.81B-14.5%
Amylyx Pharmaceuticals, Inc. logo
Amylyx Pharmaceuticals, Inc.AMLX
$1.31B+414%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$16.77B+178%
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
$1.63B+45.1%

Other financials

Income statement

See full
Operating income-$27.3M-2.8%
Net income-$23.5M+1.5%
EPS (diluted)-$0.50+29.6%

Balance sheet

See full
Cash & equivalents$45.2M+51.2%
Total debt$555.0K+327%
Total equity$437.8M+85.9%
Total assets$452.7M+84.1%

Cash flow

See full
Operating cash flow-$20.2M+10.9%
CapEx$437.0K+1,357%
Free cash flow-$20.6M+9.1%

Valuation

See full
Market cap$2.21B+475%

Returns & leverage

See full
Return on equity-25.7%
Debt / equity0.0×
Current ratio30.8×+7.5×

Where this comes from

Calculated from MBX Biosciences, Inc.’s reported figures.

The official record: MBX Biosciences, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about MBX Biosciences, Inc.'s enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MBX Biosciences, Inc.'s enterprise value?
MBX Biosciences, Inc. (MBX) reported enterprise value of $1.37B in Q1 2026.
How has MBX Biosciences, Inc.'s enterprise value changed year-over-year?
MBX Biosciences, Inc.'s enterprise value increased by 533.3% year-over-year, from $216.9M to $1.37B.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.